Wall Street brokerages predict that ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) will report ($0.18) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.19) in the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, December 13th.
On average, analysts expect that ESSA Pharma will report full year earnings of ($0.55) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.49). For the next year, analysts forecast that the firm will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.57). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for ESSA Pharma.
A number of research firms recently issued reports on EPIX. Zacks Investment Research upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Monday, September 11th. Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Finally, Bloom Burton cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $4.75.
ESSA Pharma (EPIX) opened at $0.26 on Wednesday. ESSA Pharma has a 12-month low of $0.25 and a 12-month high of $3.59. The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.